# Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

> **NCT07253662** · PHASE1 · RECRUITING · sponsor: **Northwell Health** · enrollment: 10 (estimated)

## Conditions studied

- Adenocarcinoma Pancreas

## Interventions

- **DEVICE:** PIPAC
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT07253662
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-12-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253662, "Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07253662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*